COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Protocol No
GOG-3028/C-750-01
Principal Investigator
Denise Uyar
Phase
II
Description
To assess whether AGEN23034 administered alone or combination with another drug AGEN1884 response well to women with recurrent/persistent metastatic cervical cancer
Participating Institutions
Froedtert Hospital
Status
SRC APPROVAL
Sub Category
Gynecologic Cancers
ClinicalTrials.gov
go to website